Cargando…

KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib

As tyrosine kinase inhibitors (e.g., Imatinib, IM) fail to induce long-term response in some chronic myeloid leukemia (CML), novel therapies targeting leukemia-dysregulated pathways are necessary. Nuclear-cytoplasmic trafficking of proteins play a key role in the development of leukemia and drug res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Danian, Huang, Kezhi, Yin, Songmei, Li, Yiqing, Xie, Shuangfeng, Ma, Liping, Wang, Xiuju, Wu, Yudan, Xiao, Jie, Wang, Jieyu, Yang, Wenjuan, Liu, Hongyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913223/ https://www.ncbi.nlm.nih.gov/pubmed/29707241 http://dx.doi.org/10.1038/s41420-018-0049-2

Ejemplares similares

Lineage switch from lymphoma to myeloid neoplasms: First case series from a single institution
por: Yang, Wenjuan, et al.
Publicado: (2022)

Quercetin induces autophagy-associated death in HL-60 cells through CaMKKβ/AMPK/mTOR signal pathway: Quercetin induces autophagic cell death in AML
por: Xiao, Jie, et al.
Publicado: (2022)

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
por: Garg, Manoj, et al.
Publicado: (2016)

mPGES-1/PGE2 promotes the growth of T-ALL cells in vitro and in vivo by regulating the expression of MTDH via the EP3/cAMP/PKA/CREB pathway
por: Li, Yiqing, et al.
Publicado: (2020)

KPT-330 has antitumour activity against non-small cell lung cancer
por: Sun, H, et al.
Publicado: (2014)

Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells
por: Xu, Jing, et al.
Publicado: (2023)

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
por: Shafique, Michael, et al.
Publicado: (2019)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Growth of T-cell lymphoma cells is inhibited by mPGES-1/PGE2 suppression via JAK/STAT, TGF-β/Smad3 and PI3K/AKT signal pathways
por: Li, Yiqing, et al.
Publicado: (2022)

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
por: Subhash, Vinod Vijay, et al.
Publicado: (2018)

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
por: Garg, Manoj, et al.
Publicado: (2017)

KPT330 improves Cas9 precision genome- and base-editing by selectively regulating mRNA nuclear export
por: Cui, Yan-ru, et al.
Publicado: (2022)

Clinical analysis of 11 cases of nocardiosis
por: Li, Yiqing, et al.
Publicado: (2021)

Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway
por: Zhao, Cheng, et al.
Publicado: (2022)

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
por: Tremblay, Gabriel, et al.
Publicado: (2021)

KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling
por: Wen, Tiantian, et al.
Publicado: (2023)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2015)

XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis
por: Zhu, Zhi-Chuan, et al.
Publicado: (2019)

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2016)

The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice
por: Hightower, Rylie M., et al.
Publicado: (2020)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

330 grabados originales
por: Manilla, Manuel
Publicado: (1971)

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia
por: Singh, Surjit, et al.
Publicado: (2016)

KPT6566 induces apoptotic cell death and suppresses the tumorigenicity of testicular germ cell tumors
por: Sun, Ruijing, et al.
Publicado: (2023)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Health Tract No. 330: The Guillotine
Publicado: (1868)

Next-Generation SINE Compound KPT−8602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD
por: English, Katherine G., et al.
Publicado: (2022)

Cytotoxicity of Isoxazole Curcumin Analogs on Chronic Myeloid Leukemia-Derived K562 Cell Lines Sensitive and Resistant to Imatinib
por: Feriotto, Giordana, et al.
Publicado: (2023)

Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation
por: Jin, Hua, et al.
Publicado: (2013)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
por: Sadowski, Abbey R., et al.
Publicado: (2018)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4beuj3b5gfufqcq45cbgp1m758